Tanzisertib
CAS No. : 899805-25-5
(Synonyms: CC-930)
| Size | Price | Stock |
|---|---|---|
| 5mg | $110 | In-stock |
| 10mg | $182 | In-stock |
| 25mg | $425 | In-stock |
| 50mg | $680 | In-stock |
| 100mg | $965 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-15495 |
| M.Wt: | 448.44 |
| Formula: | C21H23F3N6O2 |
| Purity: | >98 % |
| Solubility: | DMSO : ≥ 33 mg/mL;1M HCl : 100 mg/mL (ultrasonic;adjust pH to 1 with HCl) |
Tanzisertib (CC-930) is a potent JNK1/2/3 inhibitor with IC50s of 61/7/6 nM, respectively. IC50 & Target:IC50: 61 nM (JNK1), 7 nM (JNK2), 6 nM (JNK3)[1] In Vitro: Tanzisertib (CC-930) inhibits the formation of phospho-cJun in human PBMC stimulated by phorbol-12-myristate-13-acetate and phytohemeagglutinin (IC50=1 μM)[1]. Tanzisertib (CC-930) (1-2 μM) substantially reduces hepatocyte apoptosis and necrosis, abrogates apoptosis and necrosis in FC-loaded WT hepatocytes[2]. Tanzisertib (CC-930) blocks the JNK pathway that is activated by pro-fibrotic cytokines in systemic sclerosis[3]. In Vivo: Tanzisertib (CC-930) (10 and 30 mg/kg, p.o.) inhibits the production of TNFa by 23% and 77% in the acute rat LPS-induced TNFa production PK-PD model[1]. Tanzisertib (CC-930) (150 mg/kg) prevents the development of fibrosis in different models, but can also induce the regression of pre-existing fibrosis[3].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Tanzisertib
- Cat. No.:
- HY-15495
- Quantity:
Your information is safe with us.